Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment and prevention of parvovirus B19 infection

Jeanne A Jordan, PhD
Section Editors
Martin S Hirsch, MD
Morven S Edwards, MD
Deputy Editor
Allyson Bloom, MD


Human parvovirus B19 infections are common. They are usually mild or asymptomatic, and do not require treatment. In some cases, however, infection is associated with sufficiently severe complications that treatment is indicated and may be lifesaving.

The major clinical manifestations that can occur with B19 infection include:

Erythema infectiosum

Arthritis or arthralgia

Transient aplastic crisis


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Dec 15, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.
  2. Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 1990; 33:1297.
  3. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.
  4. Saag KG, True CA, Naides SJ. Intravenous immunoglobulin treatment of chronic parvovirus B19 arthropathy. Arthritis Rheum 1993; 36(Suppl):S67.
  5. Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child 1987; 62:585.
  6. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.
  7. Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS 2000; 14:7.
  8. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56:968.
  9. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.
  10. Naides SJ, Howard EJ, Swack NS, et al. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993; 168:101.
  11. Chen MY, Hung CC, Fang CT, Hsieh SM. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 2001; 32:1361.
  12. Ware AJ, Moore T. Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:E122.
  13. Arribas JR, Peña JM, Echevarría JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med 2000; 132:1011.
  14. Finkel TH, Török TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343:1255.
  15. Oeda E, Shinohara K, Inoue H, Nomiyama J. Parvovirus B19 infection causing severe peripheral blood thrombocytopenia and persistent viremia. Am J Hematol 1994; 45:274.
  16. Kerr JR, Curran MD, Moore JE, et al. Persistent parvovirus B19 infection. Lancet 1995; 345:1118.
  17. Seng C, Watkins P, Morse D, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect 1994; 113:345.
  18. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.
  19. Centers for Disease Control (CDC). Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38:81.
  20. Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.
  21. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151.
  22. Zuffi E, Manaresi E, Gallinella G, et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 2001; 14:151.
  23. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166.
  24. Kerr JR, O'Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994; 163:65.
  25. Adler SP, Koch WC. Human parvovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th Ed, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.867.
  26. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675.
  27. B-19 parvovirus vaccine study by clinical trials. http://clinicaltrialsfeed.org/clinical-trials/show/NCT00379938 (Accessed on August 07, 2008).
  28. Bernstein DI, El Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011; 29:7357.